Deep science. Clear strategy. Medicines that reach patients.
Credence experts advise pharma, biotech and life-sciences companies on CMC, regulatory, quality and strategy. Real-world, deep expertise from drug discovery and product development through to approval for NCEs, 505(b)(2)s and generics. Independent, evidence-led and accountable advisory in supporting clients to bring molecules to markets.
Green-field API and formulation plants or brown-field upgrades: we build the direction, systems and documentation that carry your facility through global audits.
9
Compliance projects completed
5
Ongoing engagements in Formulation & API, targeting FDA, WHO, EU & PIC/S
8
Consultants with 5 to 20 years industry experience
B.Pharm · MSc · PhD
Consultant credentials in Chemistry & pharmaceutical sciences
Technical and regulatory diligence on deal timelines. Data-room review, risk identification, expert reporting, and a regulatory roadmap for day one post-transaction.
Discovery and lead-optimization support with phase-appropriate formulation design. Programs set up to succeed from the first batch.
PIER 02
Engineer the span
Scale-up, tech-transfer, validation and clinical bioequivalence. The load-bearing work that makes a formulation manufacturable and approvable.
PIER 03
File & launch
eCTD filings for the US and EU, approval support and launch. Bench to commercial, one continuous crossing.
Program management
Workstreams, stage gates and risk, held on one plan.
PMP-certified leads with real R&D depth run the timeline, the risk register and the partners against it, so a program crosses its stage gates on plan rather than on hope.
An independent partnership of scientists, regulators and strategists.
Founded in 2018, Credence Pharma Consulting is an independent advisory firm. We give emerging biotech, generics and established pharma clear, compliant paths from discovery to commercialization. Our advice answers to the science, never to a manufacturing or commercial agenda.
No manufacturing stake. No partner agenda. Our only interest is getting your product to patients, so the advice you get is the advice you need.
Scientific rigour
Counsel from a team that has developed 100+ NCEs, 505(b)(2)s and generics across oral solids, injectables, nasal and specialised delivery. Operators, not observers.
04 / Case studies
An NCE gastric-retention modified-release tablet for diabetes. Developed and scaled through Phase 1 to 3 CMC, tech-transferred for process-validation batches. Approved and launched in the US in January 2023.
Gastric-retention MR program for diabetes
Boston-based biotech · NCE · Phase 1 to 3 CMC · Approved January 2023
Tell us where your program stands: discovery, development, filing or launch. We will map the line that carries it successfully to the next stage-gate towards commercialization.
Credible partners for pharmaceutical & life-sciences clients. Evidence-led advisory in CMC, regulatory, quality and strategy for NCEs, generics and branded-generics.